Histopathology of pediatric nonalcoholic fatty liver disease

By J. Schwimmer, Cynthia Behling, R. Newbury, R. Deutsch, C. Nievergelt, Nicholas J. Schork, J. Lavine. Hepatology, 2005

745 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/fbb329d12e4bf4706861805ae91131086a37fd59

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Z. Younossi
2. M. Rinella
3. A. Sanyal
4. K. Cusi
5. E. Brunt
6. C. Day
7. S. Bellentani
8. J. Lavine

In Surgery

1. B. Grygiel-Górniak

Citations in the corpus

• ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (2011, background): “This pattern has been more often seen in pediatric cases of NAFLD.20 It is currently not known if this pattern is associated with a different natural history than those with definite steatohepatitis.”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “In children, NASH is characterized by portal inflammation and fibrosis, azonal steatosis and infrequent ballooning or perisinusoidal fibrosis [136].”
• Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review (2014, background): “It also plays also a prominent role in the pathogenesis of fatty liver disease (FLD) and ligands of this receptor might be effective in the reduction of hepatic staetosis by increasing energy utilization [32,33].”
• Prevalence of Fatty Liver in Children and Adolescents (2006, neutral): “5) Gender, n (%)b Male 531 (72) 364 (68) 78 (80) 18 (82) Female 211 (28) 168 (32) 19 (20) 4 (18) Race/ethnicity, n (%)c Asian 67 (9) 51 (10) 6 (6) 3 (14) Black, non-Hispanic 81 (11) 69 (13) 4 (4) 2 (9) Hispanic 250 (34) 161 (30) 45 (46) 5 (23) White, non-Hispanic 328 (44) 243 (46) 37 (38) 9 (41) Oth”
• Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. (2006, background): “Both AFLD and NAFLD generally begin as hepatic steatosis, and if the cause persists, this steatosis invariably progresses to steatohepatitis, cirrhosis, and liver cancer (2, 6, 10, 15, 21, 25).”
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012, background): “Children are reported with NAFLD as early as 2 years and with NASH-related cirrhosis as early as age 8.(183,184)”
• Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents (2011, neutral): “Fasting serum glucose, mg/dL 87 (8) 90 (10) 90 (9) 89 (9)”
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “6% when adjusted for age, sex, race, and ethnicity.((124)) A recent meta-analysis demonstrated the pooled mean prevalence of NAFLD to be 7.”